Elysia Medical Product Profile
Key Indicators
- Authorised Capital ₹ 3.25 Cr
as on 11-12-2024
- Paid Up Capital ₹ 3.25 Cr
as on 11-12-2024
- Company Age 7 Year, 1 Month
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 8.16 Cr
as on 11-12-2024
- Revenue 110.13%
(FY 2022)
- Profit -67.08%
(FY 2022)
- Ebitda -1679.39%
(FY 2022)
- Net Worth -79.78%
(FY 2022)
- Total Assets 35.94%
(FY 2022)
About Elysia Medical Product
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 3.25 Cr and a paid-up capital of Rs 3.25 Cr.
The company currently has active open charges totaling ₹8.16 Cr.
Manish Prasad and Rishika Kumari serve as directors at the Company.
- CIN/LLPIN
U74999BR2017PTC036511
- Company No.
036511
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
11 Dec 2017
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Patna
Industry
Company Details
- Location
Patna, Bihar, India
- Telephone
- Email Address
- Website
-
- Social Media
Who are the key members and board of directors at Elysia Medical Product?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Manish Prasad  | Director | 03-Jul-2019 | Current |
| Rishika Kumari | Director | 11-Dec-2017 | Current |
Financial Performance of Elysia Medical Product.
Elysia Medical Product Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 110.13% increase. The company also saw a substantial fall in profitability, with a 67.08% decrease in profit. The company's net worth observed a substantial decline by a decrease of 79.78%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Elysia Medical Product?
In 2021, Elysia Medical Product had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Laxmi Green City Construction Private LimitedActive 10 years 2 monthsManish Prasad is a mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 31 Jan 2023 | ₹4.81 M | Open |
Others Creation Date: 30 Jun 2022 | ₹2.60 M | Open |
State Bank Of India Creation Date: 31 Dec 2019 | ₹7.42 Cr | Open |
How Many Employees Work at Elysia Medical Product?
Elysia Medical Product has a workforce of 0 employees as of May 04, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Elysia Medical Product, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Elysia Medical Product's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
